| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 188.81 | 3.5% | 21.9% |
| Total Income | 188.81 | 3.5% | 21.9% |
| Expenditure | 171.98 | 2.1% | 5.7% |
| PBT | 17.11 | 6.1% | 1587.8% |
| Net Profit | 14.91 | 0.3% | 2393.8% |
| OPM | 8.91% | 1.29pp | 13.97pp |
| NPM | 7.90% | 0.25pp | 8.32pp |
| EPS | 0.27 | 3.9% | 2800.0% |
Repligen Reports Q3 2025 Revenue Up 22% and Updates 2025 Guidance
04 May 2026 · 4 May, 8:42 am
Summary
Repligen Corporation reported its Q3 2025 financial results, with revenue reaching $189 million, a 22% increase year-over-year. Organic growth was 18%. The company is raising its full-year revenue guidance to $729 to $737 million, reflecting a 14% to 15.5% non-COVID organic growth. All franchises posted double-digit year-over-year revenue and order growth.
Key Highlights
- 1
Repligen reported revenue of $189 million in Q3 2025, a 22% year-over-year increase as reported and 18% organic.
- 2
Orders increased sequentially and were greater than 20% year-over-year.
- 3
The company is increasing revenue guidance to a range of $729 to $737 million, representing 14% -15.5% year-over-year non-COVID organic growth.
- 4
GAAP gross profit was $101 million compared to $77 million in the prior year.
- 5
GAAP earnings per share was $0.26 on a fully diluted basis, compared to ($0.01) in the prior year.
- 6
Cash and cash equivalents at September 30, 2025, were $749 million, compared to $757 million at December 31, 2024.
Management Comments
Olivier Loeillot
“We had another outstanding quarter in Q3 with 18% organic growth. We are thrilled with the momentum we are seeing across our broad, differentiated portfolio and the continued execution by our team. This resulted in double-digit revenue growth across all franchises and geographies. Consumables and capital equipment revenues were strong again, with continued performance from biopharma and CDMOs. “Given our year-to-date performance of 16% organic non-COVID revenue growth and our very strong Q3 orders, we are raising our full-year revenue guidance again.”
Informational and educational content only. Not investment advice.